Iran's medicine prices surge amid US sanctions and blockade

Iran's healthcare system is under mounting pressure as medicine prices surge across the country, with some treatments becoming scarce and others becoming unaffordable for ordinary Iranians. The price increases stem from a combination of US economic sanctions and a blockade of Iranian ports that has restricted the country's ability to import essential pharmaceutical ingredients and finished medicines. The disruption comes as Iran's broader economy faces significant headwinds, with inflation affecting food, fuel, and other essential goods.

The pharmaceutical sector has proven particularly vulnerable to external economic pressure due to its heavy reliance on imported raw materials and active pharmaceutical ingredients. While major hospital shortages have not yet materialised, retail pharmacies across the country are grappling with reduced stock and escalating costs that are straining household budgets already hit by currency depreciation and rising unemployment.

Iran's economic difficulties have intensified over the past seven months as regional tensions have escalated and international restrictions have tightened. The Iranian currency has lost approximately half its value in recent weeks, further eroding purchasing power for medicines and other vital goods. The situation reflects a broader economic struggle as international pressure combines with domestic challenges to test the country's resilience.

Government officials have acknowledged the severity of the pharmaceutical crisis and called for international assistance and diplomatic solutions. Industry experts warn that prolonged supply disruptions could eventually force Iran's healthcare system to ration certain medicines or shift towards domestic alternatives that may not match the efficacy of established treatments.